COVID-19 Continues To Hinder Teva Opioid Settlement – Although Deal Is ‘Close’
Teva ‘Optimistic’ About Proposed Framework; But ‘Pessimistic’ About Timing
Uncertainty over resolving opioids litigation led Teva to write down the value of its goodwill by more than $4bn in 2020. Management has provided the latest update on getting a deal over the line and removing a significant legal overhang.
